CFM
ACET icon

Catalyst Funds Management’s Adicet Bio ACET Stock Holding History

Catalyst Funds Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-856
Closed -$19.7K – 309
2024
Q3 		$19.7K Hold
856
– – ﹤0.01% 1085
2024
Q2 		$16.6K Buy
+856
New +$22.9K ﹤0.01% 741

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Catalyst Funds Management's ACET Position: Q4 2024 in Review

Catalyst Funds Management sold out of Adicet Bio (ACET) in Q4 2024, closing a stake of 856 shares — an estimated $19.7K sold.

Catalyst Funds Management first reported a position in ACET in Q2 2024 and held it in 2 quarters. The position peaked at $19.7K in Q3 2024. 64 funds tracked by Wall St. Rank hold ACET as of Q4 2024.

  • Catalyst Funds Management reported no remaining Adicet Bio position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 856 Adicet Bio shares in Q4 2024, an estimated $19.7K.
  • Catalyst Funds Management first reported a position in Adicet Bio in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Adicet Bio position peaked at $19.7K in Q3 2024.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.